L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease is the primary cause of death in patients with end stage renal disease
(ESRD). New research suggests that the high risk of death may be partly due to high levels of
fibrosis and a loss of small blood vessels in the heart of patients with dialysis-dependent
ESRD. This study is designed to compare the effects of two different drugs, spironolactone
and L-arginine, with placebo on structure and function of the heart in individuals with
dialysis-dependent ESRD.
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborators:
Beth Israel Deaconess Medical Center Joslin Diabetes Center Massachusetts General Hospital